Fresenius Kabi Colombia SAS

Fresenius Kabi Colombia SAS is a Colombian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Bogotá, Colombia, the company operates under the legal structure of a Sociedad por Acciones Simplificada (SAS), a simplified joint-stock company. Its primary activity involves the wholesale trade of medicinal pharmaceutical products, cosmetics, and toiletries.

As a subsidiary of the global healthcare company Fresenius Kabi, Fresenius Kabi Colombia SAS plays a pivotal role in the Colombian pharmaceutical distribution network. The parent company, Fresenius Kabi, is renowned for its commitment to life, providing essential medicines and technologies for infusion, transfusion, and clinical nutrition. In Colombia, the subsidiary focuses on ensuring the availability and distribution of these critical healthcare products, thereby supporting the local healthcare infrastructure and patient care.

Fresenius Kabi Colombia SAS maintains a centralized distribution model with its primary warehouse located in Funza, Cundinamarca, a municipality near Bogotá. The facility is situated in the Parque Celta Trade complex, specifically in Bodega 22, Autopista Medellín Km 7, Funza - Cundinamarca. (mesagil.invima.gov.co) This strategic location facilitates efficient logistics and distribution throughout Colombia, ensuring timely delivery of pharmaceutical products to various regions. While the company primarily serves the Colombian market, its affiliation with the global Fresenius Kabi network suggests potential access to international distribution channels, enhancing its capacity to meet diverse healthcare needs.

In Colombia's pharmaceutical supply chain, Fresenius Kabi Colombia SAS functions as a primary wholesaler and importer. The company is responsible for sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and distributing them to local healthcare providers, including hospitals, clinics, and pharmacies. By importing and wholesaling these products, Fresenius Kabi Colombia SAS ensures the availability of essential medications and medical technologies critical for patient care in Colombia.

Fresenius Kabi Colombia SAS exhibits a high degree of supplier concentration, sourcing all its imported pharmaceutical products from a single supplier: Fresenius Kabi Oncology Limited. This supplier dependency is evident from the company's import data, which shows a total import value of $3.7 million USD across 85 shipments, all originating from this sole supplier. The top five imported products—Docetaxel, Paclitaxel, Oxaliplatin, Carboplatin, and Bortezomib—account for 100% of the company's imports from India.

This single-source dependency presents both strategic advantages and potential risks. On the positive side, a concentrated supplier base can lead to streamlined procurement processes, stronger supplier relationships, and potentially better pricing due to bulk purchasing. However, the lack of diversification also exposes the company to risks such as supply chain disruptions, price fluctuations, and dependency on the financial and operational stability of a single supplier. The absence of alternative suppliers in the import data indicates a need for strategic consideration regarding supplier diversification to mitigate potential risks.

The resilience of Fresenius Kabi Colombia SAS's supply chain is closely tied to the stability and reliability of its sole supplier, Fresenius Kabi Oncology Limited. Given the exclusive sourcing arrangement, any disruptions affecting this supplier—such as production issues, regulatory challenges, or geopolitical events—could significantly impact the company's ability to maintain a consistent supply of pharmaceutical products. The company's import data indicates a total of 85 shipments from this supplier, suggesting a consistent and ongoing relationship.

However, the lack of alternative suppliers in the import data highlights a potential vulnerability in the supply chain. To enhance resilience, it would be prudent for Fresenius Kabi Colombia SAS to explore the inclusion of additional suppliers, particularly those with recognized Good Manufacturing Practice (GMP) certifications from reputable bodies such as the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Diversifying the supplier base would not only mitigate risks associated with single-source dependency but also provide flexibility in responding to market demands and regulatory changes.

The current sourcing pattern of Fresenius Kabi Colombia SAS, characterized by a single-source dependency on Fresenius Kabi Oncology Limited, has significant strategic implications. While this concentrated approach may offer operational efficiencies and cost benefits, it also exposes the company to potential supply chain disruptions and limits its ability to negotiate favorable terms with multiple suppliers.

For Indian pharmaceutical exporters, the existing supplier concentration presents both challenges and opportunities. The absence of alternative suppliers in the import data indicates a potential gap in the market that could be addressed by offering high-quality products with recognized GMP certifications. By meeting the regulatory standards required by Colombian authorities and demonstrating the ability to supply consistent and reliable products, Indian exporters could position themselves as viable alternatives to the current sole supplier, thereby diversifying the supply chain and reducing dependency risks for Fresenius Kabi Colombia SAS.

In Colombia, the primary regulatory authority overseeing pharmaceutical imports and ensuring the safety, efficacy, and quality of medical products is the National Institute for Food and Drug Surveillance (INVIMA). INVIMA is responsible for evaluating and approving the importation of pharmaceutical products, ensuring they meet the country's health and safety standards. (mesagil.invima.gov.co)

The key legislation governing pharmaceutical imports in Colombia includes the Health Code and the Decree 677 of 1995, which establish the regulatory framework for the importation, distribution, and commercialization of pharmaceutical products. These regulations outline the requirements for obtaining marketing authorization, conducting quality control, and ensuring compliance with Good Manufacturing Practices (GMP). For Indian pharmaceutical exporters, understanding and adhering to these regulations is crucial for successful market entry and sustained operations in Colombia.

Import licensing in Colombia requires that pharmaceutical products obtain marketing authorization from INVIMA before they can be imported and distributed. This process involves submitting detailed product dossiers, including information on manufacturing processes, quality control measures, and clinical data, to demonstrate compliance with Colombian health standards. Additionally, products must be accompanied by certificates of analysis and other documentation as specified by INVIMA.

Colombia recognizes GMP certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian pharmaceutical exporters seeking to supply Fresenius Kabi Colombia SAS must ensure that their manufacturing facilities hold valid GMP certifications from these recognized organizations. This certification serves as evidence of the manufacturer's commitment to producing high-quality pharmaceutical products and is a critical requirement for import approval in Colombia.

Pharmaceutical products imported into Colombia are subject to rigorous quality control measures, including batch testing and stability studies, to ensure their safety and efficacy. Manufacturers must provide certificates of analysis and comply with INVIMA's requirements for quality assurance.

Labeling requirements stipulate that product labels be in Spanish and include essential information such as the product name, active ingredients, dosage form, strength, batch number, expiration date, storage conditions, and the manufacturer's details. Additionally, labels must include a clear statement of the product's intended use and any necessary warnings or precautions.

Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. Each unit of sale must have a unique serial number, which is recorded in a centralized database accessible to regulatory authorities and stakeholders. This system facilitates the monitoring of product movements and ensures that only authorized products are available in the Colombian market.

Between 2024 and 2026, Colombia implemented several regulatory changes affecting pharmaceutical imports. These changes included updates to the Health Code and Decree 677 of 1995, introducing stricter requirements for marketing authorization, quality control, and labeling. Notably, there was an increased emphasis on the recognition of international GMP certifications, with a focus on those from WHO and PIC/S, to ensure that imported products meet global quality standards.

Additionally, Colombia enhanced its serialization and track-and-trace systems to combat counterfeit pharmaceuticals. These measures required that all imported pharmaceutical products be serialized and that detailed records of their distribution be maintained, facilitating better monitoring and control of the pharmaceutical supply chain.

Fresenius Kabi Colombia SAS's product strategy focuses on the importation and distribution of oncology medications, specifically targeting treatments for various types of cancer. The company's import data reveals a concentration in oncology products, with the top five imported items—Docetaxel, Paclitaxel, Oxaliplatin, Carboplatin, and Bortezomib—accounting for 100% of its imports from India.

This strategic focus aligns with the growing demand for cancer treatments in Colombia, driven by an increasing incidence of cancer cases and a need for effective therapies. By concentrating on oncology, Fresenius Kabi Colombia SAS aims to address critical healthcare needs and establish a strong